Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to determine the most effective dose of BAy 46-9003 associated to
taxotere for first-line treatment of patient with prostatic cancer.
BAY 43-9006 (SORAFENIB) is a novel dual-action Raf kinase and VEGFR inhibitor, which is
orally available and has a favorable safety profile in patients with advanced solid tumors.
This, together with the antitumor activity observed after treatment with BAY 43-9006
(SORAFENIB), provides a rationale for further evaluation in patients with advanced cancer.
The recommended dose of BAY 43-9006 (SORAFENIB) for future studies is 400 mg bid as a
continuous dosing schedule.
Phase:
Phase 1
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain